2024年10月10日,生物技术股诺瓦瓦克斯医药(NVAX.US)盘中股价大涨5.05%,一度创下13.32美元的新高,引发市场热议。此番股价大涨主要受到机构分析师利好评级预期的推动。
根据消息,莱利金融分析师Mayank Mamtani在最新研报中,维持了对诺瓦瓦克斯医药的"买入"评级,并将公司目标价从23美元上调至26美元。分析师给予看好评级的主要理由是,该公司最新季度营收和利润数据表现亮眼,尤其是营收达4.15亿美元,净利润更是高达1.62亿美元。
分析师乐观预期进一步推动了投资者对诺瓦瓦克斯医药未来业绩的信心。公司目前市盈率为-5.06倍,估值水平依然较为合理。一旦公司盈利持续改善,股价还有进一步上涨空间。来自机构的利好评级和预期成为诺瓦瓦克斯医药本次盘中大涨的主导原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.